Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps im

Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has received a consensus recommendation of "Moderate

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagn

Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's f

The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical re

Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more co

Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently publ

Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a

The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical re

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the

HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises th

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix NASDAQ: BDSX reported second-quarter 2026 revenue growth of 34% year over year, supported b

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus E

Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.0

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagno

bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock of

LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagno

Shares of Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) have received an average rating of "Modera

Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating a

Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the

Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so

Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's ana

HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy r

BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the

Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.00

Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.81) per share which beat the analyst consens

2026 Financial OutlookThe Company anticipates generating between $106-112 million in total revenue i

Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.49) per share which beat the analyst consens

XOM: -1.5% | Trump 'Inclined' To Keep Exxon Mobil Out Of Venezuela: 'Didn't Like The

U.S. stock futures were swinging on Thursday following Wednesday's mixed moves. Futures of major